GW 405833
CAS: 180002-83-9
Ref. 3D-FHA00283
5mg | Descontinuado | ||
10mg | Descontinuado | ||
25mg | Descontinuado | ||
50mg | Descontinuado | ||
100mg | Descontinuado |
Informação sobre produto
- (2,3-Dichloro-Phenyl)-[5-Methoxy-2-Methyl-3-(2-Morpholin-4-Yl-Ethyl)-Indol-1-Yl]-Methan
- (2,3-Dichloro-Phenyl)-[5-Methoxy-2-Methyl-3-(2-Morpholin-4-Yl-Ethyl)-Indol-1-Yl]-Methanone
- (2,3-Dichlorophenyl)[5-methoxy-2-methyl-3-[2-(4-morpholinyl)ethyl]-1H-indol-1-yl]methanone
- 1-(2,3-Dichlorobenzoyl)-5-methoxy-2-methyl-(3-(morpholin-4-yl)ethyl)-1H-indole hydrochloride
- 1-[(2,3-dichlorophenyl)carbonyl]-5-methoxy-2-methyl-3-(2-morpholin-4-ylethyl)-1H-indole
- 1H-Indole, 1-(2,3-dichlorobenzoyl)-5-methoxy-2-methyl-3-[2-(4-morpholinyl)ethyl]-
- GW405833 hydrochloride
- Gw 405833
- L 768242
- Methanone, (2,3-dichlorophenyl)[5-methoxy-2-methyl-3-[2-(4-morpholinyl)ethyl]-1H-indol-1-yl]-
- Ver mais sinónimos
GW 405833 is a cannabinoid that has been shown to have antinociceptive and anti-inflammatory effects. It is a CB2 receptor agonist, which can be used to treat bowel disease. GW 405833 binds to the CB2 receptor and inhibits the production of inflammatory cytokines in the intestine, relieving symptoms of bowel disease. The pharmacological treatment with GW 405833 has been shown to reduce serum aminotransferase levels in mice with liver cells and improve neuronal function. This drug also causes an increase in camp levels in mouse liver cells.